AB
DNTH icon

Amalgamated Bank’s Dianthus Therapeutics DNTH Stock Holding History

Amalgamated Bank’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-769
Closed -$32K – 1961
2025
Q4 		$32K Buy
769
+237
+45% +$9.19K ﹤0.01% 1949
2025
Q3 		$21K Sell
532
-295
-36% -$7.54K ﹤0.01% 2095
2025
Q2 		$15K Hold
827
– – ﹤0.01% 2234
2025
Q1 		$15K Hold
827
– – ﹤0.01% 2175
2024
Q4 		$18K Hold
827
– – ﹤0.01% 2149
2024
Q3 		$23K Hold
827
– – ﹤0.01% 2071
2024
Q2 		$21K Buy
+827
New +$19.9K ﹤0.01% 2095
2022
Q2 		– Sell
-296
Closed -$14K – 3076
2022
Q1 		$14K Buy
+296
New +$16.2K ﹤0.01% 2894

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amalgamated Bank's DNTH Position: Q1 2026 in Review

Amalgamated Bank sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 769 shares — an estimated $32K sold.

Amalgamated Bank first reported a position in DNTH in Q1 2022 and held it in 8 quarters. The position peaked at $32K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Amalgamated Bank reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 769 Dianthus Therapeutics shares in Q1 2026, an estimated $32K.
  • Amalgamated Bank first reported a position in Dianthus Therapeutics in Q1 2022 and held it in 8 quarters.
  • Amalgamated Bank's Dianthus Therapeutics position peaked at $32K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.